Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients

NCT04369846 is registered in ClinicalTrials.gov with Xantho Biotechnology Co., LTD as lead sponsor.

NCT NCT04369846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04369846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients
Lead sponsor
Xantho Biotechnology Co., LTD
Phase
Phase 1/2
Overall status
Completed
Start date
May 4, 2020
Completion date
February 24, 2025
Enrollment
76 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis